Date: Wednesday, June 22, 2022

Time: 12:00 PM EDT / 9:00 AM PDT / 4:00 PM UTC

Duration: 30 minutes

QuartzBio-22June22-webinar-social-image

Register Now:

Summary

Clinical and translational teams must monitor biomarker samples across global site footprints and dispersed networks of labs and biorepositories.

It’s easy to get bogged down by managing the day-to-day requirements of keeping studies on track. With samples as the critical first step toward data generation, modern trials demand a unified approach for evaluating vendor and site performance and their impact on sample operations.

Join our webinar to learn how our team has been working with sponsor clients to create program and enterprise wide visibility into site and vendor metrics that inform future study planning.

We will show how clients are using key performance indicators (KPIs) including:

  • Protocol & consent deviations – compare planned vs actual events at sites and labs, including unexpected or unconsented sample collections
  • Turnaround times – monitor sample receipt to testing and data delivery
  • Sample handling & movements – uncover trends at sites and vendors, such as samples that have been delivered past processing windows
  • Sample metadata – including processing volume and quality metrics such as cell count and viability

You’ll see how teams are gaining visibility into these KPIs to streamline daily operations, while simultaneously revealing program-wide insights.

Register Now >>

About the presenter:

QuartzBio, part of Precision for Medicine, delivers technology-enabled solutions to accelerate drug development.

Bioinformatics Strategy Meeting QuartzBio 2022
Bioinformatics Strategy Meeting QuartzBio 2022

Join QuartzBio at the 8th Annual Bioinformatics Strategy Meeting East Coast USA for the “Omics-Driven Approaches” track on 23 May 2022.

ROUNDTABLE DISCUSSION: “Turning Multi-omic Data Chaos into Translational Insights”

Mike Waters of QuartzBio will facilitate a discussion among 10-15 industry leaders around critical topics relevant to biomarker-rich clinical trials:

Read more